Qu Biologics has been testing an immunologic agent for treating Crohn's disease in Canada. Now clinical trials are available in the United States that uses Site Specific Immunomodulators (SSIs) for managing the form of IBD, reports Kathleen Blanchard from EmaxHealth.com.
The biological pharmaceutical company reopened clinical trials in the U.S because of so much interest, "said Dr. Hal Gunn, M.D. in a press release.
According to the company, 30 U.S. patients will be accepted into Phase 1/2 clinical trials to investigate the safety and efficacy of QBECO SSI, for Crohn's disease. The trial is located in Vancouver, Canada.
“QBECO SSI aims to stimulate the innate immune system to remove the underlying trigger for this disease and therefore, presents a possible new treatment option for people living with Crohn’s disease, Dr. Gunn explains.
Ten patients treated for Crohn's with the therapy reported their symptoms improved. Seven patients had complete resolution after 3 months or more of treatment and four continued to experience remission after stopping QBECO SSI and all other medications.
Other finding from the trial included three patients who reported Crohn's disease remission having been confirmed on colonoscopy and CT scan. The company notes all of the patients were treated under a "compassionate" use program versus a controlled blinded clinical trial, meaning the results don't prove the drug's effectiveness.
A total of 121 patients with cancer and Crohn's disease have been treated with QBECO SSI with no serious side effects. The drug was well tolerated. For more information about Crohn's treatment with QBECO SSI, visit www.qucrohnstrial.com.
The idea behind the Crohn's therapy is to boost the body's own immune system to reverse inflammation that becomes chronic in cases of autoimmune diseases.
Reported under http://www.emaxhealth.com/178
The biological pharmaceutical company reopened clinical trials in the U.S because of so much interest, "said Dr. Hal Gunn, M.D. in a press release.
According to the company, 30 U.S. patients will be accepted into Phase 1/2 clinical trials to investigate the safety and efficacy of QBECO SSI, for Crohn's disease. The trial is located in Vancouver, Canada.
“QBECO SSI aims to stimulate the innate immune system to remove the underlying trigger for this disease and therefore, presents a possible new treatment option for people living with Crohn’s disease, Dr. Gunn explains.
Ten patients treated for Crohn's with the therapy reported their symptoms improved. Seven patients had complete resolution after 3 months or more of treatment and four continued to experience remission after stopping QBECO SSI and all other medications.
Other finding from the trial included three patients who reported Crohn's disease remission having been confirmed on colonoscopy and CT scan. The company notes all of the patients were treated under a "compassionate" use program versus a controlled blinded clinical trial, meaning the results don't prove the drug's effectiveness.
A total of 121 patients with cancer and Crohn's disease have been treated with QBECO SSI with no serious side effects. The drug was well tolerated. For more information about Crohn's treatment with QBECO SSI, visit www.qucrohnstrial.com.
The idea behind the Crohn's therapy is to boost the body's own immune system to reverse inflammation that becomes chronic in cases of autoimmune diseases.
Reported under http://www.emaxhealth.com/178
